BioMarin Pharmaceutical (NASDAQ:BMRN) announced its earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.13, ARN reports. The company had revenue of $136.80 million for the quarter, compared to the consensus estimate of $134.33 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.
A number of analysts have recently weighed in on BMRN shares. Analysts at Goldman Sachs Group Inc. reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday. They now have a $76.00 price target on the stock. On a related note, analysts at UBS AG raised their price target on shares of BioMarin Pharmaceutical to $67.00 in a research note to investors on Friday. Finally, analysts at Stifel Nicolaus raised their price target on shares of BioMarin Pharmaceutical from $67.00 to $70.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. BioMarin Pharmaceutical has a consensus rating of “Buy” and an average target price of $68.21.
Shares of BioMarin Pharmaceutical (NASDAQ: BMRN) traded up 0.14% during mid-day trading on Friday, hitting $63.91. BioMarin Pharmaceutical has a one year low of $36.28 and a one year high of $71.56. The stock’s 50-day moving average is currently $59.6. The company’s market cap is $8.884 billion.
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.